These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 34331459)
1. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. Zamai L; Rocchi MBL Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459 [TBL] [Abstract][Full Text] [Related]
2. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895 [TBL] [Abstract][Full Text] [Related]
3. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months. Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396 [TBL] [Abstract][Full Text] [Related]
4. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial). Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032 [TBL] [Abstract][Full Text] [Related]
5. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related]
6. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090 [TBL] [Abstract][Full Text] [Related]
8. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M Front Immunol; 2022; 13():811020. PubMed ID: 35126395 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis. Manomaipiboon A; Phumisantiphong U; Maneerit J; Chalearmchai Y; Jirawathin W; Prajongsai A; Phankavong P; Trakarnvanich T Vaccine; 2022 Jan; 40(4):587-593. PubMed ID: 34969542 [TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548 [TBL] [Abstract][Full Text] [Related]
12. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age. Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809 [TBL] [Abstract][Full Text] [Related]
13. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939 [TBL] [Abstract][Full Text] [Related]
14. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2. Plüß M; Mese K; Kowallick JT; Schuster A; Tampe D; Tampe B Front Immunol; 2021; 12():784145. PubMed ID: 35116025 [TBL] [Abstract][Full Text] [Related]
15. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271 [TBL] [Abstract][Full Text] [Related]
16. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. Jarius S; Bieber N; Haas J; Wildemann B J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110 [TBL] [Abstract][Full Text] [Related]
17. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
18. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports. Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323 [TBL] [Abstract][Full Text] [Related]
19. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. Azamor T; Horbach IS; Brito E Cunha D; Melgaço JG; Silva AMVD; Tubarão LN; Azevedo AS; Santos RT; Alves NDS; Machado TL; Silva J; Souza AF; Bayma C; Rocha VP; Frederico ABT; Dias BM; Setatino BP; Denani CB; Campos SPDC; Schwarcz WD; Sucupira MV; Mendes EP; Silva EDD; Barbosa de Lima SM; Ano Bom APD; Missailidis S Viruses; 2022 Aug; 14(9):. PubMed ID: 36146723 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]